Klin Farmakol Farm. 2021;35(2):88-93 | DOI: 10.36290/far.2021.014

Oral manifestations of pharmacological treatment of systemic diseases

Beáta Bolerázska1, Anna Birková2
1 I. stomatologická klinika UPJŠ LF a UNLP, Košice
2 Ústav lekárskej a klinickej biochémie UPJŠ LF, Košice

In the aging population, the number of prescription drugs for the treatment of systemic diseases is also constantly increasing. In particular, the desired or therapeutic effect of the drug is expected during pharmacological therapy. As the volume of pharmacotherapy in the population increases, it can be predicted that the incidence of adverse reactions, including oral ones, will also continue to increase. These manifestations can also be confused with the onset of a new disease, which causes a delay in causal treatment with the possible emergence of serious complications. Several diseases have been identified that can help a physician determine the possible relationship between the causes and consequences of a particular drug or group of drugs. Their pathogenesis involves complex interactions between the drug in question, other drugs, the patient's underlying disease, genetics, and environmental factors. The most common side effects in the oral cavity include xerostomia, taste disturbance, stomatitis, oral lichenoid reaction, pigmentation in harsh climates, gingival hyperplasia, bullous dermatoses and osteonecrosis. These oral manifestations have an adverse effect on oral health and also increase the risk of infection, pain, tooth loss and general health complications.

Keywords: adverse drug reactions, oral manifestations, systemic treatment.

Published: July 6, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bolerázska B, Birková A. Oral manifestations of pharmacological treatment of systemic diseases. Klin Farmakol Farm. 2021;35(2):88-93. doi: 10.36290/far.2021.014.
Download citation

References

  1. Edwards D, Boritz E, Cowen EW, Brown RS. Erythema multiforme major following treatment with infliximab. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013; 115: e36-e40. Go to original source... Go to PubMed...
  2. Yuan A, Woo SB. Adverse Drug Events in the Oral Cavity. Dermatol Clin. 2020; 38(4): 523-533. Go to original source... Go to PubMed...
  3. Choi JH, Kim MJ, Kho HS. Oral Health-Related Quality of Life and Associated Factors in Patients with Xerostomia. Int J Dent Hyg. 2021 doi: 10.1111/idh.12528. Epub ahead of print. Go to original source... Go to PubMed...
  4. Atif S, Syed SA, Sherazi UR, Rana S. Determining the relationship among stress, xerostomia, salivary flow rate, and the quality of life of undergraduate dental students. J Taibah Univ Med Sci. 2020; 16(1): 9-15. Go to original source... Go to PubMed...
  5. Agha-Hosseini F, Moosavi MS, Mirzaii-Dizgah I, Samami M. Muscarinic cholinergic receptors in minor salivary gland tissues of patients with oral lichen planus: A case-control study. J Oral Pathol Med. 2020; 49(8): 816-821. Go to original source... Go to PubMed...
  6. Scully C. Drug effects on salivary glands: dry mouth. Oral Dis. 2003; 9(4): 165-176. Go to original source... Go to PubMed...
  7. López-Álvarez J, Sevilla-Llewellyn-Jones J, Agüera-Ortiz L. Anticholinergic Drugs in Geriatric Psychopharmacology. Front Neurosci. 2019; 13: 1309. Go to original source... Go to PubMed...
  8. Van der Waal I. Oral lichen planus and oral lichenoid lesions; A critical appraisal with emphasis on the diagnostic aspects. Med Oral Patol Oral Cir Bucal. 2009; 14: E310-E314. Go to PubMed...
  9. Ferrisse TM, de Oliveira AB, Palaçon MP, da Silveira HA, Massucato EMS, de Almeida LY, Léon JE, Bufalino A. Immunohistochemical evaluation of Langerhans cells in oral lichen planus and oral lichenoid lesions. Arch Oral Biol. 2021; 124: 105027. Go to original source... Go to PubMed...
  10. Sontheimer RD. Lichenoid tissue reaction/interface dermatitis: clinical and histological perspectives. J Invest Dermatol. 2009; 129(5): 1088-1099. Go to original source...
  11. Lage D, Pimentel VN, Soares TC, Souza EM, Metze K, Cintra ML. Perforin and granzyme B expression in oral and cutaneous lichen planus 1 a comparative study. J Cutan Pathol. 2011; 38(12): 973-978. Go to original source... Go to PubMed...
  12. Lage D, Juliano PB, Metze K, de Souza EM, Cintra ML. Lichen planus and lichenoid drug-induced eruption: a histological and immunohistochemical study. Int J Dermatol. 2012; 51(10): 1199-1205. Go to original source... Go to PubMed...
  13. Van der Meij EH, Mast H, van der Waal I. The possible premalignant character of oral lichen planus and oral lichenoid lesions: A prospective five-year follow-up study of 192 patients. Oral Oncol. 2007; 43: 742-748. Go to original source... Go to PubMed...
  14. Chiang CP, Yu-Fong Chang J, Wang YP, Wu YH, Lu SY, Sun A. Oral lichen planus - Differential diagnoses, serum autoantibodies, hematinic deficiencies, and management. J Formos Med Assoc. 2018; 117(9): 756-765. Go to original source... Go to PubMed...
  15. Serrano-Sanchez P, Bagan JV, Soriano J, Sarrion G. Drug induced oral lichenoid reactions - A literature review. J Clin Exp Dent. 2010; 2: e71-e75. Go to original source...
  16. Khammissa RAG, Chandran R, Masilana A, Lemmer J, Feller L. Adverse Immunologically Mediated Oral Mucosal Reactions to Systemic Medication: Lichenoid Tissue Reaction/Interface Dermatitis-Stomatitis, Autoimmune Vesiculobullous Disease, and IgE-Dependent and Immune Complex Reactions. J Immunol Res. 2018; 2018: 7645465. Go to original source... Go to PubMed...
  17. Gawron K, Łazarz-Bartyzel K, Potempa J, Chomyszyn-Gajewska M. Gingival fibromatosis: Clinical,molecular and therapeutic issues. Orphanet J. Rare Dis. 2016; 11: 9. Go to original source... Go to PubMed...
  18. Jayakaran TG. The effect of drugs in the oral cavity - A review. J Pharm Sci Res. 2014; 6: 89-96.
  19. Dongari-Bagtzoglou, A. Informational paper: Drug-associated gingival enlargement. J. Periodontol. 2004; 75: 1424-1431. Go to original source...
  20. Mott ML, Bencivenni D, Cohen RE. Drug-induced gingival enlargement: An overview. Compend. Contin.Educ. Dent. 2013; 34: 330-336.
  21. Seymour RA, Ellis JS, Thomason JM. Risk factors for drug-induced gingival overgrowth. J Clin Periodontol. 2000; 27(4): 217-223. Go to original source... Go to PubMed...
  22. Vincent-Bugnas S, Borsa L, Gruss A, Lupi L. Prioritization of predisposing factors of gingival hyperplasia during orthodontic treatment: the role of amount of biofilm. BMC Oral Health. 2021; 21(1): 84. Go to original source... Go to PubMed...
  23. Yuan A, Woo SB. Adverse drug events in the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 119(1): 35-47. Go to original source... Go to PubMed...
  24. Bakhtiari S, Sehatpour M, Mortazavi H, Bakhshi M. Orofacial manifestations of adverse drug reactions: a review study. Clujul Med. 2018; 91(1): 27-36. Go to original source... Go to PubMed...
  25. Hatahira H, Abe J, Hane Y et al. Drug-induced gingival hyperplasia: A retrospective study using spontaneous reporting system databases. J. Pharm. Health Care Sci. 2017; 3: 1-11. Go to original source... Go to PubMed...
  26. Ruggiero SL, Dodson TB, Fantasia J et al. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014; 72(10): 1938-1956. Go to original source... Go to PubMed...
  27. Khan AA, Morrison A, Hanley DA et al. International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015; 30(1): 3-23. Go to original source... Go to PubMed...
  28. Miranda M, Gianfreda F, Raffone C, Antonacci D, Pistilli V, Bollero P. The Role of Platelet-Rich Fibrin (PRF) in the Prevention of Medication-Related Osteonecrosis of the Jaw (MRONJ). Biomed Res Int. 2021: 4948139. Go to original source... Go to PubMed...
  29. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012; 23: 1341-1347. Go to original source... Go to PubMed...
  30. Savino S, Toscano A, Purgatorio R, Profilo E, Laghezza A, Tortorella P, Angelelli M, Cellamare S, Scala R, Tricarico D, Marobbio CMT, Perna F, Vitale P, Agamennone M, Dimiccoli V, Tolomeo A, Scilimati A. Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis. Eur J Med Chem. 2018; 158: 184-200. Go to original source... Go to PubMed...
  31. de Oliveira CC, Brizeno LA, de Sousa FB, Mota MR, Alves AP. Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review. Med Oral Patol Oral Cir Bucal. 2016; 21(4): e431-e439. Go to original source... Go to PubMed...
  32. Khan AA, Morrison A, Kendler DL et al. International Task Force on Osteonecrosis of the Jaw. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. J Clin Densitom. 2017; 20(1): 8-24. Go to original source... Go to PubMed...
  33. Yoneda T, Hagino H, Sugimoto T et al. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab. 2017; 35(1): 6-19. Go to original source... Go to PubMed...
  34. Yamazaki T, Yamori M, Ishizaki T et al. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg 2012; 41: 1397. Go to original source... Go to PubMed...
  35. Nicolatou-Galitis O, Schiødt M, Mendes et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019; 127(2): 117-135. Go to original source... Go to PubMed...
  36. Pasqualetti G, Tognini S, Calsolaro V, Polini A, Monzani F. Potential drug-drug interactions in Alzheimer patients with behavioral symptoms. Clin Interv Aging. 2015; 10: 1457-1466. Go to original source... Go to PubMed...
  37. Kamath VV, Setlur K, Yerlagudda K. Oral lichenoid lesions - a review and update. Indian J Dermatol. 2015; 60(1): 102. Go to original source... Go to PubMed...
  38. Brown RS, Arany PR. Mechanism of drug-induced gingival overgrowth revisited: a unifying hypothesis. Oral Dis. 2015; 21(1): e51-e61. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.